RegulatoryCompany release

BeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC

🇺🇸 BeyondSpring Inc. (BYSI) · Fri 13 Nov 2026

The designation covers the Phase 3 DUBLIN-4 population, while BeyondSpring completes the sale of its China-linked subsidiary to Biolin and reports cash of just $0.6 million.

BeyondSpring said on 13 November 2026, alongside its third-quarter update, that the US Food and Drug Administration has granted Fast Track designation to plinabulin in combination with docetaxel. The indication is advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without actionable genomic alterations, in patients whose disease has progressed after anti-PD-(L)1 therapy and platinum-based chemotherapy.

According to the company, the designated population matches that of its Phase 3 DUBLIN-4 trial. As general context, Fast Track is an FDA programme intended to speed development and review of drugs for serious conditions with unmet need, and it allows more frequent interaction with the agency and, where criteria are met, rolling submission of an application.

BeyondSpring also reported that it closed, on 30 September, the sale of its subsidiary holding the Bulin business to Biolin. Biolin will fund roughly half of the 442-patient DUBLIN-4 enrolment in China, according to the update.

On finances, the company disclosed cash of $0.6 million and a net loss of $2.1 million for the third quarter. The source material available did not include further detail on trial timelines or on how the remaining enrolment will be financed.

What it means for your team

  • Fast Track status for the DUBLIN-4 population may allow more frequent FDA dialogue, but it does not alter the evidence needed for approval.
  • Regulatory teams tracking second-line or later NSCLC should note the narrow target group: non-squamous disease, no actionable genomic alterations, after anti-PD-(L)1 and platinum chemotherapy.
  • Biolin's funding of about half of the 442-patient enrolment in China is relevant to trial operations and the geographic make-up of the data.
  • The $0.6 million cash position is a funding-risk signal for partners and observers following the programme.

Company's press release (SEC filing): BeyondSpring Inc. ↗

Article written by VigiEye from the official source (BeyondSpring Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →